A Double-blind, Double-dummy, Randomized, 4-period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of TMC435 on the QTc Interval in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 03 May 2013
At a glance
- Drugs Moxifloxacin; Simeprevir
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Janssen R&D Ireland
- 07 Dec 2011 Actual initiation date changed from 1 Feb 2011 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 07 Dec 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 07 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.